WASHINGTON, Sept. 16, 2002 (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. (OTCBB:SPHC) announced its CEO Dr. Janet Greeson has been invited to participate as a speaker on the panel entitled "Investor Relations - the Good, the Bad, the Ugly" at the CEO Summit `02, September 25, in Washington, D.C. In addition, all CEO Summit attendees have been invited to participate in the U.S. Securities & Exchange Commission Small Business Capital Formation Forum September 26-27.
The CEO Summit's theme is "Public Companies - Trying Harder in Trying Times," and is an effort by the CEO Council, representing responsible small- and mid-cap public company executives to establish "Best Practices" to assure shareholders and investors of full disclosure and accessibility.
Keynoters include David John, Research Fellow, the Heritage Foundation, speaking on "Should the SEC Acts be Overhauled Now?" and Alan Reynolds, Senior Fellow, the Cato Institute and syndicated financial columnist, addressing the topic, "Executive Stock Options - Good for the USA?"
Other speakers include Charles Terry, CEO, Comtex News; Robert Pettit, Presidio Risk; Marty Horwitz, Repath, McAuley and Woods; James B. Parsons, Esq., Parsons Law Firm; Timothy Ryan, Issuers Services Manager, BBX, Nasdaq (invited); Michael T. Williams, Esq., Williams Law Group and Counsel; MCS Group; Wayne Jenkins, President, IR Select; John Lefebvre, Author, "Investor Relations for the Emerging Company"; Dr. Janet Greeson, CEO, Samaritan Pharmaceuticals; Mark Angelo - Managing Director, Cornell Capital Partners, LP; Raj S. Nanvaan - Managing Director, Monarch Equities; Frank Jones, Esq., Whiteford Taylor & Preston; Rhoda Anderson, RhodaAnderson.com; Stephen Bers, Esq., Whiteford Taylor & Preston and Steven Crane, CEO, CorpHQ. Topics include investor relations practices, D&O insurance, corporate governance, disclosure alternatives, executive compensation, the BBX exchange, costs of compliance, the SEC Small Business Forum, and acquiring capital in a difficult market.
The chair of the Host Committee is Stephen Day and the vice chair is Scott Carroll, President, Investrend Broadcast. The CEO Council's directors include Gerald Kern, CEO, Meditech Pharmaceuticals; Steven Crane; Steve Day; Dr. Janet Greeson, CEO Samaritan Pharmaceuticals; Gayle Essary, CEO, Investrend Communications, Inc.; Richard Mangiarelli, CEO, Cybertel Communications; and Timothy S. Novak, CEO, Surgical Safety Products.
Information about the Summit and the SEC Forum is available at http://www.ceocouncil.net or contact Stephen Day, Chair of Summit Host Committee, 301-704-3129, sday@ceocouncil.net.
About Samaritan Pharmaceuticals
Samaritan Pharmaceuticals is an emerging biopharmaceutical company that has collaborated with Georgetown University to provide its research arm. They are dedicated to saving lives by developing "breakthrough discovery" for Alzheimer's, Cancer, Cholesterol Reduction, HIV and Parkinson's. Samaritan's pipeline includes one late stage Phase II HIV drug, an Alzheimer's and Breast Cancer Diagnostic, and has discovered nine drug candidates which are in various preclinical trials.
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 26, 2002. The company undertakes no duty to update forward-looking statements.
Note: To receive future press releases and newsletters automatically, or for more information, visit the Web site at www.samaritanpharmaceuticals.com.